The online marketplace for research chemicals has grown exponentially over the past few years, and with it, the emergence of numerous sellers offering substances like 5-MeO-DALT. While it’s important to acknowledge the legitimate research purposes for which these chemicals are intended, it’s equally vital to scrutinize the vendors and their products critically.
Sellers: When considering where to buy 5-MeO-DALT or any research chemical, the reputation and credibility of the seller are paramount. Unfortunately, the market is rife with vendors of varying reliability, making it essential to research thoroughly before purchasing. Buyers should prioritize vendors with established track records, transparent business practices, and good customer reviews.
Designer Drug Status: 5-MeO-DALT is classified as a designer drug, meaning it has been created synthetically to mimic the effects of known substances while evading legal restrictions. This classification should raise caution flags for potential buyers. The lack of comprehensive research on these chemicals’ safety and long-term effects makes them a risky choice for those seeking to experiment.
Online Availability: The ease with which 5-MeO-DALT and similar research chemicals are available online is both a blessing and a curse. While accessibility can be advantageous for researchers, it also poses risks. The online nature of these transactions can attract unscrupulous sellers who prioritize profit over safety and ethics.
For Sale: The phrase “for sale” is a typical lure sellers use to attract buyers. It’s crucial to approach such listings with skepticism. Legitimate research chemical vendors typically adhere to strict regulations and guidelines, emphasizing the importance of scientific research over commercial sales.
Summary
5-Methoxy-N,N-di-allyltryptamine, also known as 5-MeO-DALT, represents a psychedelic tryptamine initially crafted by the pioneering chemist Alexander Shulgin.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 928822-98-4 |
|---|---|
| PubChem CID | 50878551 |
| ChemSpider | 21106245 |
| UNII | V25VK0QTAA |
| ChEMBL | ChEMBL2391541 |
| CompTox Dashboard (EPA) | DTXSID30239169 |
| Chemical and physical data | |
| Formula | C17H22N2O |
| Molar mass | 270.376 g·mol−1 |
Chemistry
The complete chemical nomenclature for this compound is N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl] prop-2-en-1-amine. It shares structural similarities with the compounds 5-MeO-DPT and DALT.
In April 2020, Chadeayne and colleagues successfully elucidated the crystalline structure of the unbound form of 5-MeO-DALT
Pharmacology
5-MeO-DALT binds to 5-HT1A, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, α2A, α2B, α2C, H1, κ-opioid, σ1 and σ2 receptors with Ki values lower than 10μM and also acts as a DAT and SERT monoamine reuptake inhibitor.[3]
| Binding site | pKi ± SEM at binding site |
| 5-HT1A | 7.70 ± 0.10 |
| 5-HT1B | 6.13 ± 0.04 |
| 5-HT1D | 7.00 ± 0.10 |
| 5-HT1E | 6.30 ± 0.05 |
| 5-HT2A | 6.66 ± 0.08 |
| 5-HT2B | 7.23 ± 0.05 |
| 5-HT2C | 6.34 ± 0.08 |
| 5-HT5A | 5.48 ± 0.04 |
| 5-HT6 | 6.81 ± 0.03 |
| 5-HT7 | 7.05 ± 0.07 |
| α2A | 6.67 ± 0.07 |
| α2B | 6.14 ± 0.04 |
| α2C | 5.83 ± 0.06 |
| H1 | 6.30 ± 0.06 |
| H3 | 5.77 ± 0.04 |
| κOR | 5.95 ± 0.07 |
| μOR | < 5.00 |
| σ1 | 6.52 ± 0.06 |
| σ2 | 6.60 ± 0.05 |
| DAT | 5.50 ± 0.20 |
| NET | < 5.00 |
| SERT | 6.30 ± 0.05 |
The metabolism and cytochrome P450 inhibition of 5-MeO-DALT has been described in scientific literature.
History
The initial information concerning the synthesis and effects of 5-MeO-DALT originated from Alexander Shulgin, who shared it with a research associate named Murple in May 2004. Subsequently, this information was disseminated online. By June 2004, 5-MeO-DALT was already offered by online research chemical vendors, following its production by commercial laboratories in China. In August 2004, comprehensive details regarding the synthesis and effects of 5-MeO-DALT were formally published by Erowid.
Dosage
Alexander Shulgin’s research team conducted tests using doses within the range of 12 to 20 milligrams.
Legal Status
China
As of October 2015, 5-MeO-DALT was categorized as a controlled substance in China.
Japan
Japan classified 5-MeO-DALT as a controlled substance in April 2007 through an amendment to the Pharmaceutical Affairs Law.
United Kingdom
On January 7, 2015, 5-MeO-DALT was reclassified as a Class A drug in the United Kingdom following an update to the tryptamine blanket ban.
Singapore
In Singapore, 5-MeO-DALT was included in the Fifth Schedule of the Misuse of Drugs Act (MDA), rendering it illegal as of May 2015.
Sweden
Sweden’s Riksdag designated 5-MeO-DALT as a Schedule I narcotic, categorizing it under “substances, plant materials, and fungi which normally do not have a medical use,” effective May 1, 2012. The Medical Products Agency published this classification in regulation LVFS 2012:6, and it is listed as 5-MeO-DALT N-allyl-N-(5-methoxy-1H-indol-3-yl)
United States
At the federal level in the United States, 5-MeO-DALT is not explicitly scheduled. However, it could be considered an analog of 5-MeO-DiPT, a controlled substance in the USA, or an analog of another tryptamine. In such cases, purchase, sale, or possession might be subject to prosecution under the Federal Analog Act.
Florida
In Florida, 5-MeO-DALT is classified as a Schedule I controlled substance, rendering it illegal to buy, sell, or possess within the state.
Louisiana
Similarly, in Louisiana, 5-MeO-DALT is categorized as a Schedule I controlled substance, making it illegal to buy, sell, or possess within the state.
FAQ
1. What is 5-MeO-DALT?
5-MeO-DALT, or 5-Methoxy-N, N-di-allyltryptamine, is a synthetic chemical compound in the tryptamine class. It is known for its psychoactive effects and is sometimes used recreationally or for research.
2. Is 5-MeO-DALT legal?
The legal status of 5-MeO-DALT varies from country to country and even within different regions. It is essential to check your area’s specific laws and regulations before buying, possessing, or using 5-MeO-DALT.
3. What are the effects of 5-MeO-DALT?
The impacts of 5-MeO-DALT can vary widely from person to person. Commonly reported effects include altered perception, changes in mood, and visual distortions. However, the specific experiences and intensity can differ based on dosage, individual tolerance, and set and setting.
4. How is 5-MeO-DALT typically used?
5-MeO-DALT is usually taken orally, often as capsules or powder. Some individuals may choose to insufflate (snort) it, but this method is rare.
5. Is 5-MeO-DALT safe?
The safety of 5-MeO-DALT is a subject of concern. Limited research has been conducted on its safety profile and potential long-term effects. It is crucial to exercise caution and harm reduction practices when considering its use.
6. Are there risks associated with 5-MeO-DALT use?
Like many psychoactive substances, there are risks associated with 5-MeO-DALT use. These risks may include physical and psychological discomfort, adverse reactions, and, in some cases, overdose or severe health consequences.
7. Can 5-MeO-DALT be addictive?
The addictive potential of 5-MeO-DALT is not well understood, but like other psychoactive substances, it may have the potential for psychological dependence in some individuals.
References
- In July 2023, Anvisa (Agência Nacional de Vigilância Sanitária) published “RDC Nº 804 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial” [Collegiate Board Resolution No. 804 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] in the Diário Oficial da União. This document highlights the controlled status of various substances, including 5-MeO-DALT, in Brazilian Portuguese.
- In April 2020, Chadeayne and colleagues researched 5-MeO-DALT, focusing on its crystalline form. Their findings were published in IUCrData, providing valuable insights into the chemical structure of this substance.
- Cozzi and Daley’s research in February 2016 explored receptor binding profiles and quantitative structure-affinity relationships of several 5-substituted-N, N-diallyltryptamines, shedding light on the interactions of these compounds with receptors.
- In October 2015, Michely and colleagues delved into the metabolism of 5-MeO-DALT and its detectability in urine through various analytical techniques, as outlined in the “Analytical and Bioanalytical Chemistry” journal.
- Dinger and his team’s research in January 2016 investigated the cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class, providing crucial insights into potential drug interactions.
- An interview with Alexander Shulgin conducted by Morris and Smith in May 2010 offered a glimpse into his knowledge and expertise, shedding light on the history and synthesis of psychoactive substances, including 5-MeO-DALT.
- In a YouTube video, Sasha Shulgin, known for his work in psychoactive substances, discussed 5-MeO-DALT and related compounds.
- Post’s cluster headache patient survey 2015 explored the potential use of 5-MeO-DALT as a treatment for cluster headaches, providing valuable patient perspectives.
- Post’s research in 2014 investigated the use of synthetic tryptamine N, N-diallyl-5-methoxytryptamine for treating cluster headache symptoms, contributing to the understanding of potential therapeutic applications.
- Brandt and colleagues discussed pharmacotherapy for cluster headaches in February 2020, exploring various treatment options, including the potential role of psychoactive substances.
- Schindler and his team’s study in October 2015 examined the use of indoleamine hallucinogens, including 5-MeO-DALT, in the context of cluster headaches, providing insights into patient experiences and self-reported benefits.
- China’s Food and Drug Administration issued a notice in September 2015 regarding regulating non-medical anesthetic and psychotropic substances, including 5-MeO-DALT, in China.
- The Ministry of Health, Labor, and Welfare in Japan published information about unauthorized pharmaceuticals, including 5-MeO-DALT, in July 2015.
- Singapore’s Central Narcotics Bureau (CNB) released a news release in April 2015 outlining the listing of 5-MeO-DALT as a controlled substance in Singapore.
- Sweden’s Riksdag added 5-MeO-DALT to Schedule I, categorizing it as a narcotic substance under Swedish law as of May 1, 2012.
- In the United States, 5-MeO-DALT is not explicitly scheduled at the federal level; however, it may be considered an analog of controlled substances like 5-MeO-DiPT, potentially leading to prosecution under the Federal Analog Act.
- Florida classifies 5-MeO-DALT as a Schedule I controlled substance, making it illegal to buy, sell, or possess within the state.
- Likewise, Louisiana categorizes 5-MeO-DALT as a Schedule I controlled substance, rendering it illegal to buy, sell, or possess within the state.